Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients.
作者信息
Mackman Nigel, Spronk Henri M H, Stouffer George A, Ten Cate Hugo
机构信息
From the Thrombosis and Hemostasis Program, Division of Hematology and Oncology (N.M.) and Division of Cardiology (G.A.S.), Department of Medicine, McAllister Heart Institute, University of North Carolina at Chapel Hill; and Laboratory for Clinical Thrombosis and Haemostasis, Thrombosis Expert Centre, Department of Internal Medicine (H.M.H.S., H.t.C.) and Department of Biochemistry (H.M.H.S., H.t.C.), Cardiovascular School of Medicine (Cardiovascular Research Institute Maastricht), Maastricht University Medical Centre, the Netherlands.
出版信息
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):726-732. doi: 10.1161/ATVBAHA.117.310048. Epub 2018 Feb 15.
Abstract
摘要
相似文献
1
Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients.冠状动脉疾病和外周动脉疾病患者的双重抗凝和抗血小板治疗
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):726-732. doi: 10.1161/ATVBAHA.117.310048. Epub 2018 Feb 15.
2
More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions.更多，更多，更多：超越双联抗血小板治疗降低急性冠状动脉综合征中的血栓形成——当前数据与未来方向
J Am Heart Assoc. 2018 Jan 26;7(3):e007754. doi: 10.1161/JAHA.117.007754.
3
Coronary and peripheral artery atherosclerosis: what choice for antiplatelet therapy.冠状动脉和外周动脉粥样硬化：抗血小板治疗该如何选择？
J Cardiovasc Med (Hagerstown). 2018 Feb;19 Suppl 1:e72-e74. doi: 10.2459/JCM.0000000000000557.
4
Antithrombotic therapy in peripheral artery disease.外周动脉疾病的抗栓治疗
Vasc Med. 2016 Apr;21(2):156-69. doi: 10.1177/1358863X15622987. Epub 2016 Jan 28.
5
Antithrombotic Therapy in Lower Extremity Artery Disease.下肢动脉疾病的抗血栓治疗。
Curr Vasc Pharmacol. 2020;18(3):215-222. doi: 10.2174/1570161117666190206230516.
6
Antithrombotic therapy in peripheral artery disease--antiplatelet therapy, anticoagulants, both or none.外周动脉疾病的抗栓治疗——抗血小板治疗、抗凝治疗、两者皆用或两者皆不用。
Thromb Haemost. 2010 Aug;104(2):196-9. doi: 10.1160/TH10-02-0104. Epub 2010 May 27.
7
Anticoagulation and antiplatelet therapy in patients with peripheral arterial disease of the femoropopliteal arteries.股腘动脉外周动脉疾病患者的抗凝和抗血小板治疗
J Cardiovasc Surg (Torino). 2018 Apr;59(2):164-171. doi: 10.23736/S0021-9509.17.10210-7. Epub 2017 Sep 20.
8
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).外周动脉疾病患者冠状动脉植入药物洗脱支架后的血小板反应性及临床结局：来自ADAPT-DES研究（药物洗脱支架双重抗血小板治疗评估）的分析
Circ Cardiovasc Interv. 2017 Mar;10(3). doi: 10.1161/CIRCINTERVENTIONS.116.004904.
9
Antithrombotic Therapy for Peripheral Revascularisation.外周血管重建抗栓治疗。
Curr Vasc Pharmacol. 2020;18(3):223-236. doi: 10.2174/1570161117666190206234606.
10
Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials.慢性冠状动脉疾病或外周动脉疾病患者的抗血栓治疗：随机对照试验的系统评价。
Cardiovasc Ther. 2020 Jun 23;2020:3057168. doi: 10.1155/2020/3057168. eCollection 2020.
引用本文的文献
1
Green biosynthetic silver nanoparticles from as multifunctional hemostatic agents: Combining hemostasis, antibacterial, and anti-inflammatory properties for effective wound healing.来自[具体来源]的绿色生物合成银纳米颗粒作为多功能止血剂：兼具止血、抗菌和抗炎特性以实现有效的伤口愈合。
Mater Today Bio. 2025 Jan 10;31:101468. doi: 10.1016/j.mtbio.2025.101468. eCollection 2025 Apr.
2
ANti-Thrombotic strAtegy for the management of nonocclusive thRombus with ST-segment elevation myocardial infarCtion in young pAtients - ANTARTICA study.年轻患者ST段抬高型心肌梗死非闭塞性血栓管理的抗栓策略——南极洲研究
Indian Heart J. 2025 Jan-Feb;77(1):14-21. doi: 10.1016/j.ihj.2024.12.003. Epub 2024 Dec 20.
3
Myocardial infarction following held antiplatelet therapy for lumbar radiofrequency neurotomy: A letter to the editor.腰椎射频神经切断术持续抗血小板治疗后发生心肌梗死：致编辑的一封信
Interv Pain Med. 2022 Dec 15;2(1):100171. doi: 10.1016/j.inpm.2022.100171. eCollection 2023 Mar.
4
Cardiovascular Tissue Engineering Models for Atherosclerosis Treatment Development.用于动脉粥样硬化治疗开发的心血管组织工程模型
Bioengineering (Basel). 2023 Nov 29;10(12):1373. doi: 10.3390/bioengineering10121373.
5
Plant-Derived Compounds and Extracts as Modulators of Plasmin Activity-A Review.植物源化合物和提取物作为纤溶酶活性调节剂的研究进展。
Molecules. 2023 Feb 9;28(4):1677. doi: 10.3390/molecules28041677.
6
Platelet-Neutrophil Crosstalk in Thrombosis.血小板-中性粒细胞相互作用与血栓形成。
Int J Mol Sci. 2023 Jan 9;24(2):1266. doi: 10.3390/ijms24021266.
7
Heparanase: A Novel Therapeutic Target for the Treatment of Atherosclerosis.肝素酶：治疗动脉粥样硬化的新治疗靶点。
Cells. 2022 Oct 12;11(20):3198. doi: 10.3390/cells11203198.
8
Knowledge, Attitude, and Practice Toward Cardiovascular Diseases in the Lebanese Population.黎巴嫩人群对心血管疾病的知识、态度和实践。
Glob Heart. 2022 Jul 29;17(1):47. doi: 10.5334/gh.1138. eCollection 2022.
9
The age-specific prognostic impact of the platelet-to-lymphocyte ratio on long-term outcome after acute coronary syndrome.血小板与淋巴细胞比值对急性冠状动脉综合征长期预后的年龄特异性预后影响。
Eur Heart J Open. 2021 Oct 27;2(1):oeab031. doi: 10.1093/ehjopen/oeab031. eCollection 2022 Jan.
10
Saccharides from L. root reduce platelet activation and thrombus formation in a laser injury thrombosis mouse model.来自L.根的糖类在激光损伤血栓形成小鼠模型中可降低血小板活化和血栓形成。
Exp Ther Med. 2022 May;23(5):344. doi: 10.3892/etm.2022.11274. Epub 2022 Mar 22.
本文引用的文献
1
The coagulation system in atherothrombosis: Implications for new therapeutic strategies.动脉粥样硬化血栓形成中的凝血系统：对新治疗策略的启示。
Res Pract Thromb Haemost. 2018 Feb 19;2(2):188-198. doi: 10.1002/rth2.12080. eCollection 2018 Apr.
2
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.利伐沙班联合或不联合阿司匹林治疗稳定的外周动脉或颈动脉疾病患者：一项国际、随机、双盲、安慰剂对照试验。
Lancet. 2018 Jan 20;391(10117):219-229. doi: 10.1016/S0140-6736(17)32409-1. Epub 2017 Nov 10.
3
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.利伐沙班联合或不联合阿司匹林用于稳定性冠心病患者：一项国际、随机、双盲、安慰剂对照试验。
Lancet. 2018 Jan 20;391(10117):205-218. doi: 10.1016/S0140-6736(17)32458-3. Epub 2017 Nov 10.
4
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.多中心研究：经皮冠状动脉介入治疗后实施 CYP2C19 基因指导的抗血小板治疗的结果。
JACC Cardiovasc Interv. 2018 Jan 22;11(2):181-191. doi: 10.1016/j.jcin.2017.07.022. Epub 2017 Nov 1.
5
Protease-Activated Receptor-2 Deficiency Attenuates Atherosclerotic Lesion Progression and Instability in Apolipoprotein E-Deficient Mice.蛋白酶激活受体-2缺乏减轻载脂蛋白E缺乏小鼠的动脉粥样硬化病变进展和不稳定性。
Front Pharmacol. 2017 Sep 14;8:647. doi: 10.3389/fphar.2017.00647. eCollection 2017.
6
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis.抗血小板药物治疗和预防冠状动脉粥样硬化血栓形成。
J Am Coll Cardiol. 2017 Oct 3;70(14):1760-1776. doi: 10.1016/j.jacc.2017.08.037.
7
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.利伐沙班联合或不联合阿司匹林用于稳定型心血管疾病。
N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27.
8
Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants.直接口服抗凝剂时代静脉血栓栓塞症治疗的最新进展
F1000Res. 2017 Jun 23;6:985. doi: 10.12688/f1000research.11174.1. eCollection 2017.
9
New developments in anticoagulants: Past, present and future.新型抗凝药物的进展：过去、现在和未来。
Thromb Haemost. 2017 Jun 28;117(7):1283-1288. doi: 10.1160/TH16-10-0807. Epub 2017 Jun 8.
10
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.替卡格雷与氯吡格雷在有症状外周动脉疾病中的比较。
N Engl J Med. 2017 Jan 5;376(1):32-40. doi: 10.1056/NEJMoa1611688. Epub 2016 Nov 13.
Zotero 插件